Education
About Us
Working with TipRanks
Follow Us
Cronos Australia Ltd. (AU:VIT)
ASX:VIT
VIT Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.14
Previous CloseN/A
Volume1.00K
Average Volume (3M)228.84K
Market Cap
AU$36.45M
Enterprise ValueAU$40.84M
Total Cash (Recent Filing)AU$7.58M
Total Debt (Recent Filing)AU$11.97M
Price to Earnings (P/E)10.2
Beta1.89
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Strong Equity BaseA low debt-to-equity ratio and a high equity ratio provide durable financial flexibility, reducing refinancing and default risk. This conservative capital structure supports capital allocation for R&D or commercial expansion while cushioning the business against macro shocks over the next several months.
Stable Gross MarginA sustained gross margin above 25% indicates structural cost control in production or pricing power in its specialty/generic drug segments. Stable gross margins support medium-term profitability resilience even if top-line growth softens, allowing focus on operational improvements.
Positive Medium-term Revenue TrendA positive revenue growth trend around double digits suggests expanding market penetration or product uptake. Persistent top-line growth, if maintained, underpins scale benefits, better fixed-cost absorption, and the potential to improve margins and cash generation over a 2–6 month structural horizon.
Bears Say
Severe Free Cash Flow DeclineA dramatic FCF decline and weak cash conversion from earnings signal structural liquidity stress and limited internal funding for capex or commercialization. Persistent cash weakness constrains investment, increases financing needs, and elevates execution risk over the medium term.
Low Net And Operating MarginsThin net and operating margins reduce the firm's ability to absorb cost inflation or invest in growth without diluting returns. Sustained low margins limit free cash flow expansion and make profitability improvements dependent on structural cost or revenue mix changes.
Negative EPS TrendDeclining EPS reflects deteriorating earnings power or one-off charges that have not yet been reversed. A falling EPS trend undermines reinvestment capacity and investor confidence, and unless operational performance improves, it can persistently pressure returns and capital strategy.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.05 and its highest was AU$0.14 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$36.45M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Feb 19, 2026 which is tomorrow.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Aug 24, 2025. The company reported AU$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.002.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Annually dividend of AU$0.002 which represents an annual dividend yield of 3.28%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of AU$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
―
Options Prices
Currently, No data available
---